510(k) Report

510(k) · Cleared

Cleared

cobas pulse blood glucose monitoring system

K220272510(k) Dual TrackCleared Apr 26, 2024816-day reviewClass II21 CFR 862.1345

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Roche Diagnostics · PZI Prescription Use Blood Glucose Meter For Near-Patient Testing

Cleared on Apr 26, 2024 after an 816-day review. FDA has not posted a summary or statement for it, so its predicates are not known.

Decided
Apr 26, 2024
Review
816 days
Class
Class II
Product code
PZI
Recalls
None
Predicates
0

FDA has not posted a summary or statement for it, so its predicates are not known.

FIG. 1 — Lineage of K220272Source: FDA 510(k) database · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in PZI? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new PZI device

  1. #1 K252323 cobas pulse blood glucose monitoring systemscore 12.4 · 4 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against?

FDA has not posted a summary or statement for it, so its predicates are not known.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All PZI devices

PZI Prescription Use Blood Glucose Meter For Near-Patient Testing: FDA decisions, review times, recalls and adverse event reports over 20 years. 2024, this device’s year, is highlighted.

FDA decisions per year · PZI

3in 2024

2014: 12015: 22016: 22017: 12018: 32022: 12024: 32026 (partial year): 1
2007high 3 (2018) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · PZI

816in 2024

2018: 87 days median2024: 816 days median
2007high 816 (2024) · low 87 (2018)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · PZI

5so far in 2026, the most since 2007

2024: 1, 1 Class I2026 (partial year): 5, 5 Class I
2007high 5 (2026) · low 0 (2007)2026

Class I (6 since 2007) Class II/III not classified

Adverse event reports per year · PZI

35in 2025

2019: 192020: 82021: 182022: 72023: 22024: 52025: 35
2007high 35 (2025) · low 0 (2007)2025

MAUDE reports naming product code PZI, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20141—00
20152—00
20162—00
20171—00
201838700
20190—019
20200—08
20210—018
20221—07
20230—02
202438161 (1)5
20250—035
20261—5 (5)—
Cite this page

510(k) Report. “K220272: cobas pulse blood glucose monitoring system.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K220272

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Page last updated Nov 3, 2026